Erratum to “Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells” [Redox Biology 11 (2017) 653–662](S2213231716304335)(10.1016/j.redox.2017.01.016);Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells

Redox Biology

Volumn 11, Issue , 2017, Pages 653-662

  Yang, Xiaoyu ^a   Xu, Yi ^a   Wang, Tao ^a   Shu, Dan ^b   Guo, Peixuan ^b   Miskimins, Keith ^c   Qian, Steven Y ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c SANFORD RESEARCH   (United States)

Author keywords

5 fluorouracil and gemcitabine; Cancer migration and invasion; COX catalyzed DGLA peroxidation; Delta 5 desaturase knockdown; Inhibition of histone deacetylase; ShRNA transfection

Indexed keywords

8 HYDROXYOCTANOIC ACID; ACYL COENZYME A DESATURASE 1; CYCLOOXYGENASE 2; DIHOMO GAMMA LINOLENIC ACID; FLUOROURACIL; GELATINASE A; GELATINASE B; GEMCITABINE; HISTONE DEACETYLASE; OCTANOIC ACID DERIVATIVE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; UVOMORULIN; ACYL COENZYME A DESATURASE; DELTA-5 FATTY ACID DESATURASE; PTGS2 PROTEIN, HUMAN;

ARTICLE; CANCER CELL; CANCER THERAPY; CATALYSIS; CELL INVASION; CELL MIGRATION; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; PANCREAS CANCER; PEROXIDATION; BIOSYNTHESIS; CELL MOTION; COLON TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION;

CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; FATTY ACID DESATURASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS;

EID: 85010888593     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.03.021     Document Type: Erratum

References (64)

1. [1] Keleg, S., Büchler, P., Ludwig, R., Büchler, M.W., Friess, H., Invasion and metastasis in pancreatic cancer. Mol. Cancer, 2, 2003, 14.
2. [2] Cao, H., Xu, E., Liu, H., Wan, L., Lai, M., Epithelial-mesenchymal transition in colorectal cancer metastasis: a system review. Pathol. Res. Pract. 211 (2015), 557–569.
3. [3] Ortega, A., A new role for GABA: inhibition of tumor cell migration. Trends Pharmacol. Sci. 24 (2003), 151–154.
4. [4] Zhu, P., Zhao, N., Sheng, D., Hou, J., Hao, C., Yang, X., Zhu, B., Zhang, S., Han, Z., Wei, L., Zhang, L., Inhibition of growth and metastasis of colon cancer by delivering 5-fluorouracil-loaded pluronic P85 copolymer micelles. Sci. Rep., 6, 2016, 20896.
5. [5] Quint, K., Tonigold, M., Di Fazio, P., Montalbano, R., Lingelbach, S., Rückert, F., Alinger, B., Ocker, M., Neureiter, D., Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int. J. Oncol. 41 (2012), 2093–2102.
6. [6] Andersson, R., Aho, U., Nilsson, B.I., Peters, G.J., Pastor-Anglada, M., Rasch, W., Sandvold, M.L., Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions. Scand. J. Gastroenterol. 44 (2009), 782–786.
7. [7] Zheng, C., Jiao, X., Jiang, Y., Sun, S., ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells. J. Int. Med. Res. 41 (2013), 300–306.
8. [8] Horiguchi, S., Shiraha, H., Nagahara, T., Kataoka, J., Iwamuro, M., Matsubara, M., Nishina, S., Kato, H., Takaki, A., Nouso, K., Tanaka, T., Ichimura, K., Yagi, T., Yamamoto, K., Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Mol. Oncol. 7 (2013), 840–849.
9. [9] Zhang, N., Yin, Y., Xu, S.J., Chen, W.S., 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 13 (2008), 1551–1569.
10. [10] Longley, D.B., Johnston, P.G., Molecular mechanisms of drug resistance. J. Pathol. 205 (2005), 275–292.
11. [11] Haqq, J., Howells, L.M., Garcea, G., Dennison, A.R., Targeting pancreatic cancer using a combination of gemcitabine with the omega-3 polyunsaturated fatty acid emulsion, Lipidem™. Mol. Nutr. Food Res. 60 (2016), 1437–1447.
12. [12] Hering, J., Garrean, S., Dekoj, T.R., Razzak, A., Saied, A., Trevino, J., Babcock, T.A., Espat, N.J., Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells. Ann. Surg. Oncol. 14 (2007), 3620–3628.
13. [13] Funahashi, H., Satake, M., Hasan, S., Sawai, H., Newman, R.A., Reber, H.A., Hines, O.J., Eibl, G., Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas 36 (2008), 353–362.
14. [14] Ito, H., Duxbury, M., Benoit, E., Clancy, T.E., Zinner, M.J., Ashley, S.W., Whang, E.E., Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res. 64 (2004), 7439–7446.
15. [15] Dufour, M., Faes, S., Dormond-Meuwly, A., Demartines, N., Dormond, O., PGE2-induced colon cancer growth is mediated by mTORC1. Biochem. Biophys. Res. Commun. 451 (2014), 587–591.
16. [16] Reader, J., Holt, D., Fulton, A., Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev. 30 (2011), 449–463.
17. [17] Eibl, G., Bruemmer, D., Okada, Y., Duffy, J.P., Law, R.E., Reber, H.A., Hines, O.J., PGE (2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 306 (2003), 887–897.
18. [18] Bu, X., Zhao, C., Dai, X., Involvement of COX-2/PGE (2) pathway in the upregulation of MMP-9 expression in pancreatic cancer. Gastroenterol. Res. Pract., 2011 (2011: 214269).
19. [19] Takahashi, H., Li, A., Dawson, D.W., Hines, O.J., Reber, H.A., Eibl, G., Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Pancreas 40 (2011), 453–459.
20. [20] Tomozawa, S., Nagawa, H., Tsuno, N., Hatano, K., Osada, T., Kitayama, J., Sunami, E., Nita, M.E., Ishihara, S., Yano, H., Tsuruo, T., Shibata, Y., Muto, T., Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer 81 (1999), 1274–1279.
21. [21] Chen, W.S., Wei, S.J., Liu, J.M., Hsiao, M., Kou-Lin, J., Yang, W.K., Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int. J. Cancer 91 (2001), 894–899.
22. [22] Tabolacci, C., Lentini, A., Provenzano, B., Gismondi, A., Rossi, S., Beninati, S., Similar antineoplastic effects of nimesulide, a selective COX-2 inhibitor, and prostaglandin E1 on B16-F10 murine melanoma cells. Melanoma Res. 20 (2010), 273–279.
23. [23] Sagar, P.S., Das, U.N., Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells in vitro. Prostaglandins Leukot. Ess. Fat. Acids 53 (1995), 287–299.
24. [24] Gu, Y., Xu, Y., Law, B., Qian, S.Y., The first characterization of free radicals formed from cellular COX-catalyzed peroxidation. Free Radic. Biol. Med. 57 (2013), 49–60.
25. [25] Xu, Y., Qi, J., Yang, X., Wu, E., Qian, S.Y., Free radical derivatives formed from cyclooxygenase-catalyzed dihomo-γ-linolenic acid peroxidation can attenuate colon cancer cell growth and enhance 5-fluorouracil's cytotoxicity. Redox Biol. 2 (2014), 610–618.
26. [26] Boutaud, O., Sosa, I.R., Amin, T., Oram, D., Adler, D., Hwang, H.S., Crews, B., Milne, G.L., Harris, B.K., Hoeksema, M.D., Knowllmann, B.C., Lammers, P.E., Marnett, L.J., Massion, P.P., Oates, J.A., Inhibition of the biosynthesis of prostaglandin E2 by low dose aspirin: implications for adenocarcinoma metastasis. Cancer Prev. Res. (Phila) 9 (2016), 855–865.
27. [27] Gregor, J.I., Kilian, M., Heukamp, I., Kiewert, C., Kristiansen, G., Schimke, I., Walz, M.K., Jacobi, C.A., Wenger, F.A., Effects of selective COX-2 and 5-LOX inhibition on prostaglandin and leukotriene synthesis in ductal pancreatic cancer in Syrian hamster. Prostaglandins Leukot. Ess. Fat. Acids 73 (2005), 89–97.
28. [28] Kirane, A., Toombs, J.E., Ostapoff, K., Carbon, J.G., Zaknoen, S., Braunfeld, J., Schwarz, R.E., Burrows, F.J., Brekken, R.A., Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clin. Cancer Res. 18 (2012), 5031–5042.
29. [29] Yao, M., Kargman, S., Lam, E.C., Kelly, C.R., Zheng, Y., Luk, P., Kwong, E., Evans, J.F., Wolfe, M.M., Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 63 (2003), 586–592.
30. [30] Kobayashi, H., Uetake, H., Higuchi, T., Enomoto, M., Sugihara, K., JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. BMC Cancer, 5, 2005, 26.
31. [31] Yamauchi, T., Watanabe, M., Hasegawa, H., Nishibori, H., Ishii, Y., Tatematsu, H., Yamamoto, K., Kubota, T., Kitajima, M., The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer Res. 23 (2003), 245–249.
32. [32] Hawkey, C.J., Langman, M.J.S., Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52 (2003), 600–608.
33. [33] Greenberg, J.D., Fisher, M.C., Kremer, J., Chang, H., Rosenstein, E.D., Kishimoto, M., Lee, S., Yazici, Y., Kavanaugh, A., Abramson, S.B., CORRONA investigators. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Clin. Exp. Rheumatol. 27 (2009), 395–401.
34. [34] Yu, Q., Purwaha, P., Ni, K., Sun, C., Mallik, S., Qian, S.Y., Characterization of novel radicals from COX-catalyzed arachidonic acid peroxidation. Free Radic. Biol. Med. 47 (2009), 568–576.
35. [35] Xiao, Y., Gu, Y., Purwaha, P., Ni, K., Law, B., Mallik, S., Qian, S.Y., Characterization of free radicals formed from COX-catalyzed DGLA peroxidation. Free Radic. Biol. Med. 50 (2011), 1163–1170.
36. [36] Xu, Y., Yang, X., Zhao, P., Yang, Z., Yan, C., Guo, B., Qian, S.Y., Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2. Free Radic. Biol. Med. 96 (2016), 67–77.
37. [37] Yang, X., Xu, Y., Brooks, A., Guo, B., Miskimins, K.W., Qian, S.Y., Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs. Free Radic. Biol. Med. 97 (2016), 342–350.
38. [38] Bi, G., Jiang, G., The molecular mechanism of HDAC inhibitors in anticancer effects. Cell Mol. Immunol. 3 (2006), 285–290.
39. [39] Koutsounas, I., Giaginis, C., Theocharis, S., Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?. World J. Gastroenterol. 19 (2013), 1173–1181.
40. [40] Mariadason, J.M., HDACs and HDAC inhibitors in colon cancer. Epigenetics 3 (2008), 28–37.
41. [41] Schneider, G., Krämer, O.H., Fritsche, P., Schüler, S., Schmid, R.M., Saur, D., Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J. Cell Mol. Med. 14 (2010), 1255–1263.
42. [42] Zhao, X., Yang, W., Pei, F., Ma, W., Wang, Y., Downregulation of matrix metalloproteinases contributes to the inhibition of cell migration and invasion in HepG2 cells by sodium valproate. Oncol. Lett. 10 (2015), 531–535.
43. [43] Wang, Z., Leng, Y., Tsai, L.K., Leeds, P., Chuang, D.M., Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition. J. Cereb. Blood Flow Metab. 31 (2011), 52–57.
44. [44] Mitmaker, E.J., Griff, N.J., Grogan, R.H., Sarkar, R., Kebebew, E., Duh, Q.Y., Clark, O.H., Shen, W.T., Modulation of matrix metalloproteinase activity in human thyroid cancer cell lines using demethylating agents and histone deacetylase inhibitors. Surgery 149 (2011), 504–511.
45. [45] Lee, J.C., Maa, M.C., Yu, H.S., Wang, J.H., Yen, C.K., Wang, S.T., Chen, Y.J., Liu, Y., Jin, Y.T., Leu, T.H., Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells. Mol. Carcinog. 43 (2005), 207–214.
46. [46] Quehenberger, O., Armando, A., Dumlao, D., Stephens, D.L., Dennis, E.A., Lipidomics analysis of essential fatty acids in macrophages. Prostaglandins Leukot. Ess. Fat. Acids 79 (2008), 123–129.
47. [47] Thomas, D.M., Zalcberg, J.R., 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin. Exp. Pharmacol. Physiol. 25 (1998), 887–895.
48. [48] Noordhuis, P., Holwerda, U., Van der Wilt, C.L., Van Groeningen, C.J., Smid, K., Meijer, S., Pinedo, H.M., Peters, G.J., 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann. Oncol. 15 (2004), 1025–1032.
49. [49] Shakibaei, M., Kraehe, P., Popper, B., Shayan, P., Goel, A., Buhrmann, C., Curcumin potentiates antitumor activity of 5-fluorouracil in a 3D alginate tumor microenvironment of colorectal cancer. BMC Cancer, 15, 2015, 250.
50. [50] Peng, Z.R., Zhong, W.H., Liu, J., Xiao, P.T., Effects of the combination of hyperbaric oxygen and 5-fluorouracil on proliferation and metastasis of human nasopharyngeal carcinoma CNE-2Z cells. Undersea Hyperb. Med. 37 (2010), 141–150.
51. [51] Iovieno, A., Lambiase, A., Moretti, C., Perrella, E., Bonini, S., Therapeutic effect of topical 5-fluorouracil in conjunctival squamous carcinoma is associated with changes in matrix metalloproteinases and tissue inhibitor of metalloproteinases expression. Cornea 28 (2009), 821–824.
52. [52] Buhrmann, C., Shayan, P., Kraehe, P., Popper, B., Goel, A., Shakibaei, M., Resveratrol induces chemosensitization to 5-fluorouracil through up-regulation of intercellular junctions, Epithelial-to-mesenchymal transition and apoptosis in colorectal cancer. Biochem. Pharmacol. 98 (2015), 51–68.
53. [53] de Sousa Cavalcante, L., Monteiro, G., Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. Eur. J. Pharmacol. 741 (2014), 8–16.
54. [54] Haq, M., Shafii, A., Zervos, E.E., Rosemurgy, A.S., Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 60 (2000), 3207–3211.
55. [55] Banerjee, J., Al-Wadei, H.A., Al-Wadei, M.H., Dagnon, K., Schuller, H.M., Differential modulation of nicotine-induced gemcitabine resistance by GABA receptor agonists in pancreatic cancer cell xenografts and in vitro. BMC Cancer, 14, 2014, 725.
56. [56] Liao, Z.J., Guo, Y.H., Zhao, Z., Yao, J.T., Xu, R., Nan, K.J., Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway. Int. J. Oncol. 45 (2014), 651–658.
57. [57] Quint, K., Tonigold, M., Di Fazio, P., Montalbano, R., Lingelbach, S., Rückert, F., Alinger, B., Ocker, M., Neureiter, D., Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition. Int. J. Oncol. 41 (2012), 2093–2102.
58. [58] Yu, Y., Wang, J., Xia, N., Li, B., Jiang, X., Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells. Oncol. Rep. 33 (2015), 1683–1690.
59. [59] De, U., Kundu, S., Patra, N., Ahn, M.Y., Ahn, J.H., Son, J.Y., Yoon, J.H., Moon, H.R., Lee, B.M., Kim, H.S., A new histone deacetylase inhibitor, MHY219, inhibits the migration of human prostate cancer cells via HDAC1. Biomol. Ther. 23 (2015), 434–441.
60. [60] Ahn, M.Y., Kang, D.O., Na, Y.J., Yoon, S., Choi, W.S., Kang, K.W., Chung, H.Y., Jung, J.H., Min do, S., Kim, H.S., Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett. 325 (2012), 189–199.
61. [61] Glozak, M.A., Seto, E., Histone deacetylases and cancer. Oncogene 26 (2007), 5420–5432.
62. [62] Shu, D., Shu, Y., Haque, F., Abdelmawla, S., Guo, P., Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat. Nanotechnol. 6 (2011), 658–667.
63. [63] Cui, D., Zhang, C., Liu, B., Shu, Y., Du, T., Shu, D., Wang, K., Dai, F., Liu, Y., Li, C., Pan, F., Yang, Y., Ni, J., Li, H., Brand-Saberi, B., Guo, P., Regression of gastric cancer by systemic injection of RNA nanoparticles carrying both ligand and siRNA. Sci. Rep., 5, 2015, 10726.
64. [64] Shu, D., Li, H., Shu, Y., Xiong, G., Carson, W.E. 3rd, Haque, F., Xu, R., Guo, P., Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 9 (2015), 9731–9740.